Accellix specializes in advanced technologies for automated cell phenotyping, particularly within the context of Good Manufacturing Practice (GMP) environments. Their flagship product, the Accellix Automated Cell Phenotyping Platform, is a compact, bench-top flow cytometer designed for ease of use and minimal maintenance. This platform utilizes a microfluidic cartridge system that incorporates ambient-stable reagents, allowing for automated sample preparation and enhanced reproducibility. The system is engineered for rapid assay processing, with a total running time of just 30 minutes, and features a user-friendly touchscreen interface that simplifies operation and training. The platform is particularly beneficial for quality control analytics in cell therapy manufacturing, streamlining complex testing processes.

The Accellix platform employs spectral flow cytometry, which enhances the analysis of cellular populations by capturing a broader spectrum of emitted light from fluorescent probes. This technology allows for simultaneous analysis of multiple parameters without the need for calibration or compensation adjustments, thus improving accuracy and efficiency. The system's algorithm-based autoanalysis software automates data interpretation, providing users with immediate results and facilitating traceability in compliance with regulatory standards. By integrating these advanced technologies, Accellix aims to revolutionize the field of flow cytometry, making it more accessible and effective for researchers and manufacturers in the life sciences sector.

United States

Accellix aims to enable cell and gene therapy companies to meet their key product QC requirements by providing fast and actionable multi-parameter results using the Accellix instrument and a room temperature stable cartridge. 

Accellix will continue to identify markets where its platform and assay migration expertise can be best combined to create meaningful opportunities.

Accellix

Company Details